Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
about
Interventions for mycosis fungoidesMulticentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyTreatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas.Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyPrimary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.An update on the management of peripheral T-cell lymphoma and emerging treatment optionsHow I treat the peripheral T-cell lymphomasComparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Update: peripheral T-cell lymphomas.Novel treatment avenues for peripheral T-cell lymphomas.Targeting CD30 in anaplastic large cell lymphoma.Novel therapies for peripheral T-cell lymphomas.Current state of art for transplantation paradigms in peripheral T-cell lymphomas.From empiric to mechanism-based therapy for peripheral T cell lymphoma.X. Challenges and future directions in peripheral T-cell lymphoma.Chimeric antigen receptor T-cell therapies for lymphoma.Investigational drugs for T-cell lymphoma.How to select the frontline treatment for a patient with peripheral T-cell lymphoma.Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.Chidamide in the treatment of peripheral T-cell lymphomaA Review of Autologous Stem Cell Transplantation in Lymphoma.The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.Recent advances in understanding and managing T-cell lymphoma.Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma.Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
P2860
Q24200749-4C7A236B-D674-4EE4-BA30-B93EEA3097FAQ33394912-ED0A7C7A-346A-4099-9E5E-9498FE72BD53Q33425087-DEC24E30-A363-4D3E-B3F2-9274E3812878Q33428066-8A89FE26-4FF7-4BB1-9EE9-A0D776D49458Q33434137-29C5C4B1-8DBC-47A8-BB93-13AC1761AB7EQ33435881-4CAC7C30-4CCA-48FE-A58F-B9FBC14B43FBQ34226010-E89139CF-566D-4407-82DF-E5820F3C8DCEQ35224833-0D43D6BC-9D6B-40C9-B9A3-D0EF761C8B37Q35586880-786026E2-C672-4C9F-A64E-8230B9FD5AEFQ35683871-7D3D20DD-2904-4EFA-9F3A-663F3D3B9F62Q35865090-6C7882A0-7B2D-454B-9919-E233B60215F7Q35989647-330DB9C1-ADC5-4F24-9E0A-F8195D49A209Q36360736-BD94022E-9725-4BC5-8605-A5B842BBB6B5Q37214534-6AA40737-D23A-4249-B990-2020BA9997C6Q37391571-7D61FDD5-2004-4306-9E2A-00CD5ED48F57Q37932546-65A50162-BD06-4D30-A589-3D730E32A606Q37939715-17FC80FC-56C9-4F20-8ED6-E2D1F40EB4AAQ38045460-39AC6726-8904-4F2F-8D54-60F72AA52AA2Q38052082-393BA402-6F55-4F00-BEB0-82D52A398D14Q38111388-3F563D31-56C8-46DF-AA1E-18EABC864EFBQ38132821-8E791A79-8C33-446A-A7F8-F54BFEB42872Q38186617-210AD51A-292B-431B-8F36-DAD0D3926410Q38524000-231118E8-BA25-414B-B17D-18438CE05019Q38600697-5D2F9752-5F8A-4242-B155-950995572D2DQ38635909-1C961E17-6140-46B3-900E-C4753662EB89Q38724551-27DB9FE4-213D-4C85-B3F3-98689F12895FQ38780407-C4C9E594-D884-4D56-9530-36CCC876350BQ38782072-D8FD8A92-30AB-4E24-9EE7-EBE81003FECAQ39063866-7A483264-5C45-42CF-BCFA-A75E005B0C51Q39110404-5CD71B64-60AF-4929-BBCD-5DD49F5CC1F8Q39288544-93D5A359-2288-4BBB-B1E9-6743A2E171BEQ40421573-115600B4-E1EF-4153-B321-1B04B944E12BQ41246604-82CA5644-079E-4B3D-92A9-0029C70062FEQ43765534-532F0D60-72AF-4AEB-84AA-4BE1469ADC43Q47131247-8A29EC62-EF85-4735-837A-F657DD309CBFQ48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCBQ48517926-C79BBFBB-2332-40BB-9244-59D53B8808A9Q48559035-628031C4-D919-4E42-81D9-D0E0A934F0C7Q53828417-54C5F09F-024E-45E4-A315-4ECF8290C54EQ54295957-9FF58D19-68E5-4B4C-B67E-5FC837AB5BF2
P2860
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Upfront VIP-reinforced-ABVD (V ...... phase III trial GOELAMS-LTP95.
@en
Upfront VIP-reinforced-ABVD
@nl
type
label
Upfront VIP-reinforced-ABVD (V ...... phase III trial GOELAMS-LTP95.
@en
Upfront VIP-reinforced-ABVD
@nl
prefLabel
Upfront VIP-reinforced-ABVD (V ...... phase III trial GOELAMS-LTP95.
@en
Upfront VIP-reinforced-ABVD
@nl
P2093
P50
P1476
Upfront VIP-reinforced-ABVD (V ...... phase III trial GOELAMS-LTP95
@en
P2093
Antoine Thyss
Audrey Simon
Bernard Desablens
Charles Foussard
Eric Deconinck
Frederic Maloisel
Houchingue Eghbali
Jean François Rossi
Jean Pierre Vilque
Jerome Jaubert
P2860
P304
P356
10.1111/J.1365-2141.2010.08329.X
P407
P577
2010-08-25T00:00:00Z